Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Abeona Therapeutics Inc has a consensus price target of $15.86 based on the ratings of 7 analysts. The high is $21 issued by Stifel on May 30, 2024. The low is $6 issued by SVB Leerink on November 14, 2022. The 3 most-recent analyst ratings were released by Oppenheimer, HC Wainwright & Co., and HC Wainwright & Co. on March 5, 2025, February 19, 2025, and November 25, 2024, respectively. With an average price target of $15.33 between Oppenheimer, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 194.88% upside for Abeona Therapeutics Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
03/05/2025 | Buy Now | 207.7% | Oppenheimer | Francois Brisebois44% | → $16 | Initiates | → Outperform | Get Alert |
02/19/2025 | Buy Now | 188.47% | HC Wainwright & Co. | Mitchell Kapoor45% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
11/25/2024 | Buy Now | 188.47% | HC Wainwright & Co. | Raghuram Selvaraju43% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
10/31/2024 | Buy Now | 188.47% | HC Wainwright & Co. | Raghuram Selvaraju43% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
10/29/2024 | Buy Now | 246.16% | Cantor Fitzgerald | Kristen Kluska71% | $18 → $18 | Reiterates | Overweight → Overweight | Get Alert |
09/20/2024 | Buy Now | 246.16% | Cantor Fitzgerald | Kristen Kluska71% | $18 → $18 | Reiterates | Overweight → Overweight | Get Alert |
08/14/2024 | Buy Now | 188.47% | HC Wainwright & Co. | Raghuram Selvaraju43% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
07/12/2024 | Buy Now | 188.47% | HC Wainwright & Co. | Raghuram Selvaraju43% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
07/03/2024 | Buy Now | 188.47% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $15 | Initiates | → Buy | Get Alert |
05/30/2024 | Buy Now | 303.85% | Stifel | Dae Gon Ha47% | → $21 | Initiates | → Buy | Get Alert |
05/16/2024 | Buy Now | 303.85% | Cantor Fitzgerald | Kristen Kluska71% | $28 → $21 | Maintains | Overweight | Get Alert |
04/23/2024 | Buy Now | 592.32% | Cantor Fitzgerald | Kristen Kluska71% | $36 → $36 | Reiterates | Overweight → Overweight | Get Alert |
08/24/2023 | Buy Now | 630.78% | Cantor Fitzgerald | Kristen Kluska71% | → $38 | Reiterates | Overweight → Overweight | Get Alert |
07/13/2023 | Buy Now | 630.78% | Cantor Fitzgerald | Kristen Kluska71% | → $38 | Reiterates | Overweight → Overweight | Get Alert |
05/24/2023 | Buy Now | 284.62% | Alliance Global Partners | James Molloy31% | → $20 | Reiterates | → Buy | Get Alert |
11/14/2022 | Buy Now | 15.39% | SVB Leerink | Mani Foroohar46% | $5 → $6 | Maintains | Market Perform | Get Alert |
11/08/2022 | Buy Now | 669.25% | Cantor Fitzgerald | Kristen Kluska71% | $22 → $40 | Maintains | Overweight | Get Alert |
08/11/2022 | Buy Now | -3.84% | SVB Leerink | Mani Foroohar46% | $1 → $5 | Maintains | Market Perform | Get Alert |
The latest price target for Abeona Therapeutics (NASDAQ:ABEO) was reported by Oppenheimer on March 5, 2025. The analyst firm set a price target for $16.00 expecting ABEO to rise to within 12 months (a possible 207.70% upside). 12 analyst firms have reported ratings in the last year.
The latest analyst rating for Abeona Therapeutics (NASDAQ:ABEO) was provided by Oppenheimer, and Abeona Therapeutics initiated their outperform rating.
There is no last upgrade for Abeona Therapeutics
There is no last downgrade for Abeona Therapeutics.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Abeona Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Abeona Therapeutics was filed on March 5, 2025 so you should expect the next rating to be made available sometime around March 5, 2026.
While ratings are subjective and will change, the latest Abeona Therapeutics (ABEO) rating was a initiated with a price target of $0.00 to $16.00. The current price Abeona Therapeutics (ABEO) is trading at is $5.20, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.